The most critical phase of recovery from a torn rotator cuff begins not in the surgeon's office, but in the patient's living room. Adherence to a precise, often painful, regimen of physical therapy exercises is the single greatest predictor of a successful outcome, yet it is also the point where the clinical pathway most frequently breaks down. A new startup from Seoul is betting that a smartphone camera and a clinician's dashboard, connected by artificial intelligence, can close that gap.
OrthoCare, founded in 2024 by orthopedic surgeon and professor Kim Jong-ho, is developing what it calls an integrated AI platform for musculoskeletal diagnosis and rehabilitation [FuturePlay]. Its initial focus is a digital therapeutic system for postoperative care, specifically targeting patients recovering from arthroscopic rotator cuff repair and those with adhesive capsulitis, commonly known as frozen shoulder [Health Kyunghyang, June 2025]. The company recently secured a pre-Series A round of $3.18 million, following earlier seed investments from FuturePlay and Taurus Partners [KORIT, October 2026].
The Clinical Wedge: ANAPA PS and ME
OrthoCare's approach hinges on a two-part system designed to bridge the hospital and the home. In the clinic, physicians would use ANAPA PS, an application that employs a device's camera to provide automated measurement of a patient's shoulder range of motion and muscle strength [PMC]. This objective data aims to replace subjective visual assessments, offering a standardized baseline. The prescription then flows to ANAPA ME, a patient-facing mobile application that guides the individual through prescribed rehabilitation exercises at home, using the phone's camera to provide form feedback and track compliance [PMC].
Early pilot data suggests the technical core is viable. A study listed in PubMed, which appears to reference the ANAPA system, reported that its automated measurement functions demonstrated "technical reliability and measurement consistency for monitoring rehabilitation outcomes" [PubMed]. For a digital therapeutic, this kind of reproducible, objective measurement is not just a feature, it is the foundational requirement for both clinical trust and regulatory approval.
A Founder From the Front Lines
The company's origin is deeply rooted in clinical practice. Founder and CEO Kim Jong-ho is an orthopedic surgeon and professor at Catholic University Yeouido St. Mary’s Hospital in Seoul [The VC]. He began preparing the venture with support from the university's industry-academic cooperation foundation and had filed nine domestic and international patent applications prior to the company's formal launch [Health Kyunghyang, June 2025]. This academic-hospital nexus has provided a natural testing ground; OrthoCare conducted an exploratory clinical trial at Yeouido St. Mary’s Hospital in January 2025 and later signed a memorandum of understanding with the university's Department of Orthopedic Surgery for joint research [Health Kyunghyang, June 2025].
This background shapes the company's trajectory. Kim is not an outsider looking to disrupt a clinical workflow he doesn't understand. He is attempting to digitize and scale a part of his own daily practice, starting with the specific postoperative protocols he oversees. The $3.18 million in new capital is likely earmarked for advancing the clinical evidence required to cross the threshold from a pilot tool to a certified digital therapeutic device, particularly with South Korea's Ministry of Food and Drug Safety.
The Path to a Regulated Product
OrthoCare's ambitions place it squarely in the complex world of digital therapeutics (DTx), where software itself becomes a regulated medical intervention. The company's current status is that of a clinical-stage startup. Its published traction is measured in trials and partnerships, not yet in commercial revenue or widespread hospital deployments.
The roadmap from here involves clear, sequential milestones:
- Clinical validation. Expanding beyond pilot studies to robust, randomized controlled trials that can demonstrate not just technical reliability, but improved patient outcomes compared to standard care.
- Regulatory clearance. Securing approval from the South Korean MFDS, which would allow the ANAPA system to be prescribed and potentially reimbursed.
- Commercial deployment. Moving from research partnerships with its founding hospital to paid deployments in other clinical settings.
The recent funding round provides a runway to tackle the first two steps. The absence of named commercial customers or disclosed revenue at this stage is typical for a company still building its regulatory dossier.
The Risks on the Roadmap
For all its clinical grounding, OrthoCare's journey is fraught with the standard hurdles of medtech, amplified by the novelty of the DTx category. The company's success depends on navigating a gauntlet of non-technical challenges.
- Regulatory timing. The timeline for MFDS review and approval is uncertain and can stretch for years. Any significant delays could burn capital without generating commercial momentum.
- Reimbursement complexity. Even with regulatory clearance, securing insurance reimbursement for a new digital therapeutic is a separate, arduous battle that dictates real-world adoption.
- Clinical workflow integration. Persuading busy orthopedic clinics to adopt a new measurement and patient-management system requires demonstrating unambiguous time savings or outcome improvements.
- Competitive horizon. While no direct competitors are named in the available sources, the global DTx space for musculoskeletal conditions is attracting attention. OrthoCare's first-mover advantage in its specific Korean clinical niche is valuable but not indefinite.
The company's most plausible answer to these risks is its founder's embeddedness. Kim's dual role as clinician and entrepreneur theoretically streamlines clinical trial design, clinician feedback, and early adoption within his network. The bet is that this insider path can accelerate the typically glacial pace of medical innovation.
The Standard of Care, and the Gap
The patient population here is specific: individuals recovering from arthroscopic shoulder surgery or suffering from the debilitating stiffness of a frozen shoulder. Today, the standard of care is often fragmented. A patient receives a sheet of paper with illustrated exercises after surgery, with instructions to follow up with a physical therapist. Adherence is self-reported, progress is assessed in brief follow-up visits weeks apart, and setbacks can go unnoticed until the next appointment. This analog disconnect is where recovery can falter, sometimes leading to permanent loss of mobility or requiring additional interventions.
OrthoCare's system aims to make that recovery continuum visible and manageable. By providing objective metrics to the surgeon and guided, accountable exercise to the patient, it seeks to turn a black box into a transparent pathway. The next twelve months will be critical in translating its pilot data and professor-founder vision into the hardened evidence required by regulators. If it can clear that bar, the company won't just be selling software, it will be offering a new standard for how musculoskeletal healing is measured and supported, one shoulder at a time.
Sources
- [FuturePlay] FuturePlay company portfolio | https://futureplay.co/our-companies/11
- [Health Kyunghyang, June 2025] 가톨릭대 교원 창업기업 올쏘케어, 근골격계질환 디지털 … | https://orthocare.co.kr/18/?bmode=view&idx=166254330
- [The VC] The VC company profile | https://thevc.kr/orthocare
- [KORIT, October 2026] オルソケア、34億ウォン規模のプレシリーズA資金調達を完了…筋骨格系DTx、食品医薬品安全処の臨床・商用化を加速 | https://www.korit.jp/funding/healthcare/besuccess-orthocare-ai-dtx-261024/
- [PMC, retrieved 2026] Digital Therapeutics for Postoperative Rehabilitation after Arthroscopic Rotator Cuff Repair: A Single-Center, Assessor-Blinded, Randomized Pilot Study - PMC | https://pmc.ncbi.nlm.nih.gov/articles/PMC13437144/
- [PubMed, retrieved 2026] Digital Therapeutics for Postoperative Rehabilitation after Arthroscopic Rotator Cuff Repair: A Single-Center, Assessor-Blinded, Randomized Pilot Study - PubMed | https://pubmed.ncbi.nlm.nih.gov/42553900/